# A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

> **NCT02057380** · PHASE2 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 13 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** linsitinib
- **DRUG:** erlotinib
- **DRUG:** paclitaxel
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT02057380
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-16
- **Primary completion:** 2016-10-14
- **Final completion:** 2016-12-21
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02057380

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02057380, "A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02057380. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*